| Oct 30 |
Top Stock Reports for Amazon.com, Johnson & Johnson and Boston Scientific
|
| Oct 29 |
J&J and Lilly both unveil IL-23 inhibitor efficacy in Crohn’s disease
|
| Oct 29 |
J&J to seek FDA approval after small-bore Impella heart pump hits trial goal
|
| Oct 28 |
Global Psychedelic Drugs Market Expected To Reach $10.2B By 2028 Amid Growing Mental Health Crises
|
| Oct 28 |
DOJ throws wrench into J&J bankruptcy plan to settle talc suits
|
| Oct 28 |
J&J’s $8.2 Billion Talc Settlement Faces January Court Test
|
| Oct 28 |
AbbVie to Acquire Aliada Therapeutics for $1.4 Billion
|
| Oct 28 |
J&J Impella ECP heart pump meets primary endpoint
|
| Oct 28 |
Johnson & Johnson's Tremfya Seeks Expanded Use Approval After It Shares Encouraging Late-Stage Study Data In Crohn's Disease
|
| Oct 28 |
JNJ's subcutaneous Tremfya demonstrates efficacy in Crohn's
|
